Datasheet

Version: 2.0.0 Revision date: 14 Jun 2025



Panitumumab

Catalogue No.:abx831106

Panitumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EGFR, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes.

Target: EGFR

Clonality: Monoclonal

Reactivity: Human

Expression: Recombinant

Tested Applications: ELISA, WB

Host: Human

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Isotype: IgG₂ Kappa

Form: Liquid

Purity: > 95%

Purification: Purified from cell culture supernatants by Protein A/G chromatography.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

Buffer: 0.01 M PBS. pH 7.4.

CAS Number: 339177-26-3

Concentration: Batch-dependent, typically between 0.5-2.0 mg/ml.

Datasheet

Version: 2.0.0 Revision date: 14 Jun 2025



Note:

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.



2 of 2

Website: www.abbexa.com · Email: info@abbexa.com